AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02429167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial nerve non-invasive neuromodulation via PoNS device
Description: The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
Study NCT02429167 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PoNS device
Description: The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. The sham control device is physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, minimizing any neuromodulatory effect. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
Study NCT03109392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Lignocaine
Description: 2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
Study NCT03109392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine spray
Description: 10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
Study NCT03109392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined spray and nebulization
Description: Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
Study NCT05692557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The Oculus Rift's (Lenovo, Beijing, China) Fujii - Mystical Journey was the game played by the VRD group on a tablet. The game is a peaceful, ethereal voyage that passes through several surreal, natural locations.~The game combines elements of adventure, agriculture and revitalizing music. It alternates between outdoor exploration and inventive gardening. Players explore three different magical biomes. The life force in each biome is restored by interacting with the plants and animals there.
Study NCT05692557 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation
Description: The patients of the control group performed Progressive muscle relaxation technique, a relaxation technique used to control pain. It is believed that anxiety-inducing thoughts result in muscle tension and hence muscle relaxation can reduce anxiety. The relaxation technique consisted of tensing and relaxing different muscles, starting from the toes and finally involving muscles of the head and neck. It was recommended that this be done in a peaceful, distraction-free environment. The muscle groups were tensed for a period of 5 seconds and then relaxed for 30 seconds.
Study NCT03124758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP))
Description: Measurement of Noninvasive Hemoglobin (SpHb)
Study NCT00866476 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVD 1208S, a Shigella flexneri 2a live, oral vaccine
Description: CVD 1208S consists of freshly harvested ∆guaBA, ∆sen, ∆set S. flexneri 2a strain 2457T suspended in phosphate buffered saline to reach the desired inoculum Form: liquid Dose: 10 to the 9th power CFU in 1.0 ml Route: oral.
Study NCT00866476 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
Study NCT04671147 — intervention group
Intervention type: PROCEDURE
Intervention: Preoperative traction
Description: Compare two methods of preoperative traction (Cotrel traction exercises and skull tongs femoral traction)
Study NCT02666482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop Smoking SF Web App - baseline
Description: Smoking cessation web app in Spanish and English. Accessible online at no charge.
Study NCT02858037 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring
Description: Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.
Study NCT02293486 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Description: Intake of 200 ml of pomegranate juice or pomegranate juice dilution during 21 days after exercise.
Study NCT03784274 — intervention group
Intervention type: BEHAVIORAL
Intervention: Stakeholder analysis
Description: • INCLUSION CRITERIA FOR NET MAPPING ACTIVITIES: Those respondents who are directly involved or knowledgeable about pneumonia related policy environment in the country/province.~* Respondents who consent to participate in the study.~* Respondents belonging to Sindh, Punjab, Baluchistan, KPK and Islamabad.~EXCLUSION CRITERIA:~• Respondents belonging to Gilgit-Baltistan (GB), Azad Jammu and Kashmir (AJK) and Federally Administered Tribal Area (FATA). Reasons of their exclusion are newly developed governance system (GB), separate governance (AJK) and security threat (FATA).
Study NCT01696305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalobarrier
Study NCT01696305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guardix-SG
Study NCT02760433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
Study NCT02760433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
Study NCT02760433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
Study NCT02911636 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic SABR with intra-prostatic SABR
Description: described elsewhere
Study NCT01859260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP/autopap
Study NCT04443049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is \< 60 kg and 12 mg if body weight is > 60 kg
Study NCT04443049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is \< 60 kg and 12 mg if body weight is > 60 kg
Study NCT04443049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
Study NCT04443049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (Tab Mecovit) orally twice a day (BD) daily
Study NCT02498938 — intervention group
Intervention type: GENETIC
Intervention: SERPINA1 gene
Description: 2ml blood sample collected from patients to extract DNA for assessment of SERPINA1 gene polymorphism
Study NCT05025163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.23% fluoride foam application
Description: topical application of fluoride foam every 6 months
Study NCT05025163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.26% fluoride varnish application
Description: topical application of fluoride varnish every 6 months
Study NCT02840669 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac magnetic resonance imaging (CMR)
Study NCT02840669 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise-stress test
Study NCT02840669 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Echocardiography (ECHO)
Study NCT02840669 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac-related blood studies
Study NCT01037231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxalobacter formigenes
Description: NLT (not less than) 10\^7 CFU oxalobacter formigenes twice daily for 24 weeks
Study NCT01037231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02075333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ingestion of solution
Description: Participants will ingest the solution
Study NCT02075333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of solution
Description: Participants will ingest the solution
Study NCT02075333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rinising of solution
Description: Participants rinse the solution in the oral cavity
Study NCT00469014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.
Study NCT05639803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGIFNα1b
Description: 100μg/vial
Study NCT00469014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.
Study NCT00455858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
Study NCT02420964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: video instruction
Description: Patient Directed Video Instruction
Study NCT02420964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nurse instruction
Description: Nurse directed instruction
Study NCT05639803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5ml/vial
Study NCT04512183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Fidelity Simulation
Description: Teaching strategy based on high-fidelity simulation, which simulates the reality of health care to promote meaningful learning.
Study NCT04512183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-Fidelity Simulation
Description: Teaching strategy based on low-fidelity simulation, which simulates the reality of health care using less technological and less interactive mannequins.
Study NCT03564249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniCap
Description: The MiniCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan
Study NCT03246035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: For the intervention arm, a specialized heart failure nurse practitioner will contact the patient or their primary caregiver by telephone within 5 days post-discharge and send them an education packet by mail. During the telephone call, the nurse will (1) confirm the patient's scheduled follow-up appointment in cardiology, (2) provide recommendations for heart failure self-care behaviors that were found to be deficient at baseline. Patients will then be referred to a Geriatrics Assessment Team, who will provide individualized recommendations for frailty domains that were found to be deficient at baseline. The technique used to provide educational recommendations will be motivational interviewing.
Study NCT03246035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (Standard Care)
Description: For patients randomized to the Control Group (Standard Care), they will receive their follow-up visits, medications, diet and physical activity advice as they normally would. This is the care they would receive even if they were not enrolled in the study
Study NCT02763748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic endoscopy combined surgery
Study NCT02763748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic and endoscopic cooperative surgery
Study NCT02763748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-arch laparoscopic and endoscopic cooperative surgery
Study NCT02575183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varinecline (Chantix)
Description: A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
Study NCT02575183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Varenicline)
Description: A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive a varenicline-matched. The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
Study NCT05869344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black bean protein hydrolysates (BPH)
Description: Participants were blinded to treatment and received BPH (5 g powder) dissolved in 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of BPH.
Study NCT05869344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Commercial non-caloric beverage
Description: Participants were blinded to treatment and received 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of placebo.
Study NCT00317070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl sulfoxide
Description: intravesical installation 50 ml
Study NCT00317070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC Cocktail
Description: * Heparin 10,000 units~* Gentamicin 80 mg~* Hydrocortisone sodium succinate (Solucortef) 100 mg~* Lidocaine hydrochloride 1% 10 ml~* Sodium Bicarbonate 8.4% 5 ml
Study NCT04476771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feliz-Mente (third generation psychotherapy)
Description: The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
Study NCT04149522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepitel Film®
Description: As a part of this research study, Mepitel Film® will be placed prior to a participant's first radiation treatment, and will be removed one week following the end of treatment. The Film will be placed by the physician or his/her designee to cover approximately one-half of the breast divided in the cephalo-caudal plane. The film will remain in place until one week following the completion of radiotherapy. Any loss of film applied will be replaced as needed. Application of the Film is done by research personnel clinically trained in its application procedures.
Study NCT02265211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help App
Study NCT01294254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10
Description: Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)
Study NCT01294254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site
Description: wound is covered conventionally by applying one half of the Mepilex cut
Study NCT01713985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT02575183 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Therapy
Description: This intervention is for all study participants and it involves 4 visits to the hospital. Each visit include a 30-min one-on-one individual session with the specialized therapist during which participants will be taught how to manage any withdrawal symptoms they experience, how to anticipate high-risk situations, deal with smoking triggers, achieve and maintain their goal to stop waterpipe smoking.
Study NCT02575183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: This intervention is for all study participants and it involves 4 visits to the hospital. Each visit include a 30-min one-on-one individual session with the specialized therapist during which participants will be taught how to manage any withdrawal symptoms they experience, how to anticipate high-risk situations, deal with smoking triggers, achieve and maintain their goal to stop waterpipe smoking.
Study NCT01713985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermage
Description: Radiofrequency treatment focusing radiofrequency energy
Study NCT04578145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HIV self-testing among female sex workers
Description: Barriers faced by FSWs in terms of undergoing HIV blood test seemingly overcome through the implementation of alternative strategy of testing, by using OFT self-testing (Ora-Quick).~Ora-Quick test used in this study measures antibody in oral fluid of participants. The oral fluid is collected used a test swab from participant's gum by wiping upper and lower gums once. The specimen mixed with buffered developer solution in test tube. Test result will appear in a short time, by 20 to 40 minutes and leading to interpret.
Study NCT00856752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
Study NCT00856752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Reference test: Single intravenous administration of 2 mg NRL972
Study NCT00856752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
Study NCT01709877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Description: Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease
Study NCT01709877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystectomy
Description: Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease
Study NCT02466269 — intervention group
Intervention type: PROCEDURE
Intervention: The supratemporalis approach
Description: The supratemporalis approach was applied in treatment of diacapitular condylar fractures
Study NCT02875522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized, non-linear aerobic exercise training
Description: Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation
Study NCT02875522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized, non-linear aerobic exercise training
Description: Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation
Study NCT00202852 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
Study NCT00202852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose >=12.5 mg/week given orally or parenterally, maximum 20 mg/week
Study NCT00202852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 3 mg/kg given as an infusion at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX